According to a report published by Grand View Research, Inc.; the global antisense and RNAi therapeutics market is projected to be worth around USD 1.81 billion by 2025. Rising use of antisense technology to study gene function for disease management is anticipated to propel market growth over the forecast period (2014 to 2025). This technology regulates expression of disease-causing genes allowing better management of diseases. In addition, increasing R&D for treatment of uncommon neurodegenerative diseases such as hereditary transthyretin amyloidosis (ATTR) is also expected to boost market in near future.
Rising collaborations between pharmaceutical companies and drug delivery service providers are anticipated to drive the market. Antisense therapeutics offer precise and effective gene silencing. Various gene silencing drugs are in late stages of development. Adoption of antisense therapeutics to overcome challenges such as unspecific modes of action and delivery-associated complications are also expected to support market growth in the forthcoming years.
Advancements in personalized therapies based on antisense technology are expected to further propel market expansion. Development of nanotechnology-oriented procedures are expected to create more opportunities in the market. However, issues related to delivering drugs to desired site is the key challenge for market growth. In addition, inevitable toxic effects associated with the antisense and RNAi therapeutics may further hinder the adoption of this technology.
Full Research Report On Antisense & RNAi Therapeutics Market Analysis: www.grandviewresearch.com/industry-analysis/global-antisense-and-rni-therapeutic-market
The worldwide antisense and RNAi therapeutics market can be segmented on the basis of technology, application, route of administration, and region. Based on technology, the market can be categorized into RNA interference and antisense RNA. In 2016, RNA interference technology held the largest revenue share due to various advantages of the technology. The RNA interface segment is further bifurcated into Small Interfering RNA (siRNA) and microRNA (miRNA). MiRNA is used to attain deeper understanding related to cancer metastasis as it involves in maintaining identity of cells. SiRNA enables induction at advanced stages of cancer growth as compared to chemotherapy. Thus, adoption of RNAi therapy to target Single Nucleotide Polymorphisms (SNPs) in genetic disorders is likely to propel market during the forecast period.
As per application, the market can be characterized into oncology, cardiovascular, respiratory disorders, renal diseases, neurodegenerative disorders, genetic disorders, infectious diseases, and others. Oncology is anticipated to continue witnessing significant growth over the forecast period due to existence of significant pipeline for cancer therapies. Demand for effective tumor targeting vectorization systems and multiple genes targeting oligonucleotide drugs is expected to grow as nanoparticle systems are affected by inter- and intra-tumor heterogeneity.
On the basis of route of administration, the market for antisense and RNAi therapeutics can be divided into pulmonary delivery, intravenous injections, intradermal injections, topical delivery, intraperitoneal injections, and others. Several studies are being carried out to reduce problems associated with rapid drug elimination without desired pharmacological action. This factor is expected to drive R&D in intravenous injections during the forecast period. Liver is considered as an ideal target for evolving technologies and can be targeted easily by intravenous route. High prevalence of liver disorders like hepatitis B and hepatitis C is likely to drive demand for RNAi therapeutics and antisense nucleotides over the forecast period.
Browse More Reports Of This Category By Grand View Research At: www.grandviewresearch.com/industry/pharmaceuticals
Geographically, the market can be divided into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America is considered as a key market due to the presence of pipeline RNAi therapeutics in U.S. Several drug applicants under clinical trials have revealed favorable results and are rolling through the development phases. This factor is anticipated to boost regional market over the forecast period.
Prominent companies operating in the antisense and RNAi therapeutics market include Enzon Pharmaceuticals Inc.; Bio-Path Holdings Inc.; Sirnaomics Inc.; Bio-Path Holdings Inc.; and Benitec Biopharma Ltd. Investments in R&D and collaborations remain the key strategies adopted by major market players to attain greater market share. Most companies are also adopting mergers and acquisitions to maintain dominance over other players. This factor is projected to create business opportunities in the forthcoming years.
Explore the BI enabled intuitive market research database, Navigate with Grand View Compass, by Grand View Research, Inc.
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
Country: United States